ORIC Oric Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ORIC
Price (delayed)
$9.66
Market cap
$938.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$862.34M
ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist
Highlights
Oric Pharmaceuticals's equity has increased by 47% QoQ and by 7% YoY
The quick ratio has grown by 35% since the previous quarter and by 7% year-on-year
ORIC's net income is down by 24% year-on-year and by 3.3% since the previous quarter
The EPS has declined by 7% year-on-year
Key stats
What are the main financial stats of ORIC
Market
Valuations
Earnings
Shares outstanding
97.12M
Market cap
$938.21M
Enterprise value
$862.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$149.67M
Net income
-$137.25M
EBIT
-$137.25M
EBITDA
-$136.06M
Free cash flow
-$121.31M
Per share
Balance sheet
Liquidity
EPS
-$1.89
EPS diluted
-$1.89
Free cash flow per share
-$1.55
Book value per share
$4.56
Revenue per share
$0
TBVPS
$4.44
Total assets
$346.86M
Total liabilities
$22.86M
Debt
$0
Equity
$324M
Working capital
$273.07M
Debt to equity
0
Current ratio
16.13
Quick ratio
15.65
Net debt/EBITDA
0.56
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-47.1%
Return on equity
-51.8%
Return on invested capital
-64.2%
Return on capital employed
-41.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORIC stock price
How has the Oric Pharmaceuticals stock price performed over time
Intraday
-2.72%
1 week
4.55%
1 month
-12.02%
1 year
-10.8%
YTD
19.7%
QTD
-4.83%
Financial performance
How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$149.67M
Net income
-$137.25M
Gross margin
N/A
Net margin
N/A
ORIC's net income is down by 24% year-on-year and by 3.3% since the previous quarter
The operating income has declined by 20% year-on-year and by 2.1% since the previous quarter
Price vs fundamentals
How does ORIC's price correlate with its fundamentals
Growth
What is Oric Pharmaceuticals's growth rate over time
Valuation
What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 7% year-on-year
Oric Pharmaceuticals's equity has increased by 47% QoQ and by 7% YoY
The stock's P/B is 8% less than its last 4 quarters average of 2.3
Efficiency
How efficient is Oric Pharmaceuticals business performance
Oric Pharmaceuticals's return on invested capital has decreased by 41% YoY and by 4.1% QoQ
The return on equity has declined by 29% year-on-year
The ROA has declined by 28% year-on-year
Dividends
What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORIC.
Financial health
How did Oric Pharmaceuticals financials performed over time
The total assets has grown by 43% since the previous quarter and by 5% year-on-year
The quick ratio has grown by 35% since the previous quarter and by 7% year-on-year
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has increased by 47% QoQ and by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.